Ex vivo distribution of gold nanoparticles in choroidal melanoma
Authors Kanavi MR, Asadi S, Ahmadieh H
Received 14 March 2017
Accepted for publication 14 October 2017
Published 30 November 2017 Volume 2017:12 Pages 8527—8529
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Thomas Webster
Mozhgan Rezaei Kanavi,1 Somayeh Asadi,1,2 Hamid Ahmadieh2
1Ocular Tissue Engineering Research Center, 2Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Studies on combined radiotherapy and nanoparticles (NPs) have shown that a greater therapeutic ratio can be achieved using gold nanoparticles (GNPs) as radiosensitizing agents within the tumor.1 Recent Monte Carlo studies demonstrated that GNPs enhance the absorbed dose by choroidal melanoma during brachytherapy with sources such as 103Pd and 125I.2 Given that the energy range of these sources is low, NPs with high atomic number can be suitable to yield a higher absorbed dose when used alongside the mentioned sources.3 Although it has been a long time since the merit and priority of using NPs in treating cancer by low-energy sources has been studied, regarding eye cancers a major concern has been the way these NPs would be spread in the ocular tissues. A principal question is the form and method by which the NPs disperse within the intraocular tumor after intralesional injection. Will the NPs be also absorbed by the nearby healthy tissues?
Corrigendum for this paper has been published.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]